Follicular thyroid cancer avid on C-11 Methionine PET/CT

Mads Rye Jochumsen, Peter Iversen and Anne Kirstine Arveschoug
Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark

Summary
A case of follicular thyroid cancer with intense focal Methionine uptake on 11C-Methionine PET/CT is reported here. The use of 11C-Methionine PET in differentiated thyroid cancer is currently being investigated as a surrogate tracer compared to the more widely used 18F-FDG PET. This case illustrates the potential incremental value of this modality, not only in the localizing of parathyroid adenoma, but also indicating that 11C-Methionine PET might have a potential of increasing the pretest likelihood of thyroid malignancy in a cold nodule with highly increased Sestamibi uptake.

Learning points:
- 11C-Methionine PET/CT and 18F-Fluorocholine PET/CT often visualizes the parathyroid adenoma in case of negative Tc-99m-MIBI SPECT/CT.
- A cold nodule in Tc-99m Pertechnetet thyroid scintigraphy with a negative Sestamibi scintigraphy has a very low probability of being malignant.
- However, the pretest likelihood of thyroid cancer in a cold nodule with increased Sestamibi uptake is low.
- 11C-Methionine PET might have a potential incremental value in increasing the pretest likelihood of thyroid malignancy in a cold nodule with highly increased Sestamibi uptake.

Background
This case is interesting as it illustrates how the relatively new scan modality 11-C-Met PET, which is used for the detection of parathyroid adenomas, can have extremely important coincidental findings such as an aggressive thyroid cancer. 11-C-Met PET might have a role as a novel diagnostic procedure in thyroid cancer and in qualifying whether cold thyroid nodules with Sestamibi uptake are suspicious of malignancy or not.

Case presentation
A 66-year-old woman with a known history of osteoporosis was suspected for primary hyperparathyroidism due to persistent elevated mean parathyroid blood hormone level of 11.4 pmol/L and hypercalcemia. She was referred for a state of the art combined Tc-99m pertechnetate thyroid scintigraphy and Tc-99m Sestamibi parathyroid scintigraphy with visual simple image subtraction technique. The thyroid scintigraphy showed two cold nodules in the thyroid gland (Fig. 1A), a large nodule in the lower third of the left thyroid lobe involving the isthmus area, and another nodule laterally in the middle third of the right thyroid lobe. The cold nodule in the left thyroid lobe had intense Sestamibi uptake, with a corresponding low attenuating process on low-dose CT scan (Fig. 1B, C and D), while the nodule in the right thyroid lobe had no Sestamibi uptake (Fig. 1B). No pathological parathyroid tissue was identified, and the patient was referred for an 11C-Methionine PET/CT in order to optimize the presurgical localization of the parathyroid adenoma.

The 11C-Methionine PET showed intense Methionine uptake in the nodule in the lower third of the left thyroid...
lobe, including the isthmus area (Fig. 2A, large arrow in Figs. 2B and C), making the nodule suspicious of malignancy. Noticeably no Methionine uptake was seen in the cold nodule on the right side. Additionally, the 11C-Methionine PET showed slightly increased activity in lymph nodes located near the aorta arch and in both lung hilii, which were considered reactive (Fig. 2A, small arrows).

A pretracheal focus with increased Methionine uptake was identified posterior of the lower pole of the thyroid gland close to the midline (Fig. 3A and B), with a correlate on low-dose CT scan (Fig. 3C), suspicious of a P3-derived parathyroid adenoma located in the left thymus.

**Investigation**

Results of Tc-99m Pertechnetate thyroid scintigraphy, Tc-99m Sestamibi parathyroid scintigraphy, 11C-Methionine PET/CT and follow-up stimulated thyroglobulin test, cervical ultrasound examination and iodine-131-tracer scintigraphy are described.
Treatment

Fine-needle aspiration cytology (FNAC) showed malignant cells in the nodule in the lower left thyroid lobe and isthmus, and benign cells in the nodule in the right thyroid lobe. The patient had a simultaneous left hemithyroidectomy and extirpation of the parathyroid adenoma. Histology showed a parathyroid adenoma of 0.14 g and a follicular thyroid carcinoma with a diameter of 35 mm expanding outside its own capsule but not outside the thyroid capsule. Because of the aggressive growth, the patient also underwent a complete right hemithyroidectomy. No further malignancy was found. Subsequently, the patient was ablated with radioiodine (I-131).

Outcome and follow-up

The patient was followed clinically, biochemically and by imaging after radioiodine treatment. Six months post treatment, the patient was eucalciemic and stimulating thyroglobulin test was negative, cervical ultrasound examination and iodine-131-tracer scintigraphy showed no sign of residual cancer tissue. Thus, the patient was considered in complete remission regarding both parathyroid adenoma and thyroid cancer.

Discussion

When a state-of-the-art combined Tc-99m pertechnetate thyroid scintigraphy and Tc-99m sestamibi parathyroid scintigraphy fail to visualize a parathyroid adenoma, a supplementary 11C-Methionine PET/CT often visualizes a parathyroid adenoma, enabling focused parathyroidectomy (1, 2, 3). 18F-Fluorocholine PET/CT is an alternative add-on examination for improvement of preoperative localization of parathyroid adenoma in case of a negative parathyroid scintigraphy (4, 5). It is well known that there is a high negative predictive value of a negative sestamibi scintigraphy in qualifying whether cold nodules in Tc-99m pertechnetat thyroid scintigraphy are benign or malignant. However, the positive predictive value is low (6, 7). Methionine is needed for protein synthesis, as a biological methyl donor for the methylation of DNA, transfer-RNA and other compounds (transmethylation) after formation of 5-adenosylmethionine (SAM). 11C-Methionine PET is in a clinical setting used to evaluate the extent and recurrence of brain tumors, as Methionine accumulates in viable cancer cells (8). Furthermore 11C-Methionine PET has been suggested as a diagnostic tool in qualifying whether an 18F-FDG PET positive solitary lung nodule is malignant or benign (9). The use of 11C-Methionine PET in differentiated thyroid cancer is currently being investigated as a surrogate tracer compared to the more widely used 18F-FDG PET; however, 11C-Methionine PET has not proven to be superior to 18F-FDG PET in the detection of recurrent disease in differentiated thyroid cancer (10, 11). Methionine uptake in a benign colloid nodule has previously been described (12). It is possible that the tumor would have had a similar uptake of Fluorochoiline, as differentiated thyroid cancer previously have shown positive on 18F-Fluorocholine PET/CT (13, 14, 15). This case illustrates the potential incremental value of 11C-Methionine PET/CT, not only in the localizing of parathyroid adenoma, but also indicating that 11C-Methionine PET might have a potential of increasing the pretest likelihood of thyroid malignancy in a cold nodule with highly increased sestamibi uptake. Further studies with larger sample size are needed to determine the performance of 11C-Methionine PET/CT in classification of cold sestamibi-uptaking thyroid nodules into benign and malignant, as well as to determine the cost-effectiveness of such an add-on examination.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Patient consent

Written informed consent has been obtained from the patient for the publication of this report.

Author contribution statement

Mads Rye Jochumsen: scan analysis and writer of the primay draft; Peter Iversen: scan analysis especially the follow-up scans, proof reading and feedback; Anne Kirstine Arveschoug: supervision, proof reading, feedback.

References

1 Weber T, Gottstein M, Schwenzer S, Beer A & Luster M. Is C-11 methionine PET/CT able to localise Sestamibi-negative parathyroid adenomas? World Journal of Surgery 2017 41 980–985. (https://doi.org/10.1007/s00268-016-3795-4)
2 Yuan L, Liu J, Kan Y, Yang J & Wang X. The diagnostic value of 11C-methionine PET in hyperparathyroidism with negative 99mTc-MIBI SPECT: a meta-analysis. *Acta Radiologica* 2017 58 558–564. (https://doi.org/10.1177/02841851166616878)

3 Lenschow C, Gassmann P, Wenning C, Senninger N & Colombombo-Benkmann M. Preoperative (1)1C-methionine PET/CT enables focused parathyroidectomy in MIBI-SPECT negative parathyroid adenoma. *World Journal of Surgery* 2015 39 1750–1757. (https://doi.org/10.1007/s00268-015-2992-x)

4 Kluijfhout WP, Vorselaars WM, Vriens MR, Borel Rinkes IH, Valk GD & de Keizer B. Enabling minimal invasive parathyroidectomy for patients with primary hyperparathyroidism using Tc-99m-sestamibi SPECT-CT, ultrasound and first results of (18)F-fluorocholine PET-CT. *European Journal of Radiology* 2015 84 1745–1751. (https://doi.org/10.1016/j.ejrad.2015.05.024)

5 Michaud L, Balogova S, Burgess A, Ohmona J, Huchet V, Kerrou K, Lefevre M, Tassart M, Perie S, et al. A pilot comparison of 18F-fluorocholine PET/CT, ultrasonography and 123I/99mTc-sestamibi dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism: influence of thyroid anomalies. *Medicine* 2015 94 e1701. (https://doi.org/10.1097/MD.0000000000001701)

6 Wale A, Miles KA, Young B, Zammit C, Williams A, Quin J & Dizdarevic S. Combined (99m)Tc-methoxyisobutylisonitrile scintigraphy and fine-needle aspiration cytology offers an accurate and potentially cost-effective investigative strategy for the assessment of solitary or dominant thyroid nodules. *European Journal of Nuclear Medicine and Molecular Imaging* 2014 41 105–115. (https://doi.org/10.1007/s00259-013-2546-0)

7 Giovanella L, Suriano S, Maffioli M, Ceriani L & Spriano G. (99m)Tc-sestamibi scanning in thyroid nodules with nondiagnostic cytology. *Head and Neck* 2010 32 607–611. (https://doi.org/10.1002/hed.21229)

8 Cook GJ, Maisey MN & Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. *European Journal of Nuclear Medicine* 1999 26 1363–1378. (https://doi.org/10.1007/s002590050597)

9 Hsieh HJ, Lin SH, Lin KH, Lee CY, Chang CP & Wang SJ. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET. *Annals of Nuclear Medicine* 2008 22 533–538. (https://doi.org/10.1016/j.annnucmed.2007.0142-8)

10 Lauri C, Di Traglia S, Galli F, Pizzichini P & Signore A. Current status of PET imaging of differentiated thyroid cancer with second generation radiopharmaceuticals. *Quarterly Journal of Nuclear Medicine and Molecular Imaging* 2015 59 105–115.

11 Phan HT, Jager PL, Plukker JT, Wolfenbuttel BH, Dierckx RA & Links TP. Comparison of 11C-methionine PET and 18F-fluorodeoxyglucose PET in differentiated thyroid cancer. *Nuclear Medicine Communications* 2008 29 711–716. (https://doi.org/10.1097/MNM.0b013e328301835c)

12 Mahajan S, Tripathi M, Jaimini A & Dinesh A. False positive localisation of C-11 methionine in a colloid nodule. *Indian Journal of Nuclear Medicine* 2011 26 208–210. (https://doi.org/10.4103/0972-3919.106719)

13 Lalire P, Zalzali M, Garbar C, Bruna-Muraille C & Morland D. Incidental detection of oxyphilic papillary thyroid carcinoma by 18F-fluorocholine PET/CT. *Clinical Nuclear Medicine* 2016 41 512–513. (https://doi.org/10.1097/RLU.0000000000001181)

14 Welle CL, Cullen EL, Peller PJ, Lowe VJ, Murphy RC, Johnson GB & Binkovitz LA. (1)1C-choline PET/CT in recurrent prostate cancer and nonprostatic neoplastic processes. *Radiographics* 2016 36 279–292. (https://doi.org/10.1148/rg.2016150135)

15 Wu HB, Wang QS, Wang MF & Li HS. Utility of (1)1C-choline imaging as a supplement to F-18 FDG PET imaging for detection of thyroid carcinoma. *Clinical Nuclear Medicine* 2011 36 91–95. (https://doi.org/10.1097/RLU.0b013e318203bb55)

Received in final form 29 November 2017
Accepted 13 December 2017